Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. No abstract available.

PMID:
31029462
2.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. Erratum in: Leuk Res. 2019 Jun;81:105.

PMID:
30849661
3.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M.

Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.

4.

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.

Am J Hematol. 2018 Nov;93(11):1301-1310. doi: 10.1002/ajh.25238. Epub 2018 Sep 9.

5.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.

6.

Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients.

Rosenberg BR, Freije CA, Imanaka N, Chen ST, Eitson JL, Caron R, Uhl SA, Zeremski M, Talal A, Jacobson IM, Rice CM, Schoggins JW.

J Infect Dis. 2018 Jan 30;217(4):650-655. doi: 10.1093/infdis/jix593.

7.

Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders.

Talal AH, Chen Y, Zeremski M, Zavala R, Sylvester C, Kuhns M, Brown LS, Markatou M, Cloherty GA.

J Subst Abuse Treat. 2017 Jul;78:37-42. doi: 10.1016/j.jsat.2017.04.011. Epub 2017 Apr 20.

PMID:
28554601
8.

Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.

Zeremski M, Martinez A.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):164-168. doi: 10.1002/cpdd.312.

PMID:
28263455
9.

Response to Commentary on Zeremski et al. (2016): Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention.

Zeremski M, Sylvester C, Talal AH.

J Addict Med. 2016 Sep-Oct;10(5):364-5. doi: 10.1097/ADM.0000000000000240. No abstract available.

PMID:
27685683
10.

Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.

Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH.

J Infect Dis. 2016 Oct 15;214(8):1164-70. doi: 10.1093/infdis/jiw332. Epub 2016 Aug 2.

11.

Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention.

Zeremski M, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, Brown LS Jr, Talal AH.

J Addict Med. 2016 Mar-Apr;10(2):104-9. doi: 10.1097/ADM.0000000000000196.

PMID:
26881485
12.

IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.

Sehgal M, Zeremski M, Talal AH, Ginwala R, Elrod E, Grakoui A, Li QG, Philip R, Khan ZK, Jain P.

J Interferon Cytokine Res. 2015 Sep;35(9):698-709. doi: 10.1089/jir.2014.0211. Epub 2015 Jun 19.

13.

Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.

Sehgal M, Zeremski M, Talal AH, Khan ZK, Capocasale R, Philip R, Jain P.

J Clin Cell Immunol. 2014 Oct 31;5. pii: 1000271.

14.

Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Zeremski M, Dimova RB, Benjamin S, Penney MS, Botfield MC, Talal AH.

J Infect Dis. 2015 Jun 1;211(11):1795-9. doi: 10.1093/infdis/jiu807. Epub 2014 Dec 15.

15.

FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.

Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH.

BMC Gastroenterol. 2014 Jul 3;14:118. doi: 10.1186/1471-230X-14-118.

16.

Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell JE, Talal AH.

J Addict Med. 2014 Jul-Aug;8(4):249-57. doi: 10.1097/ADM.0000000000000041.

17.

Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Jacobson IM, Kwong AD.

Hepatology. 2014 Dec;60(6):1826-37. doi: 10.1002/hep.27202. Epub 2014 Jul 31.

18.

Gene expression analysis in serial liver fine needle aspirates.

Lejnine S, Marton MJ, Wang IM, Howell BJ, Webber AL, Maxwell JW, Shire N, Malkov V, Lunceford J, Zeremski M, Sun A, Ruddy M, Talal AH.

J Viral Hepat. 2015 Jan;22(1):64-76. doi: 10.1111/jvh.12213. Epub 2014 Jan 29.

19.

Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.

Zeremski M, Martinez AD, Talal AH.

Clin Infect Dis. 2014 Mar;58(6):880-2. doi: 10.1093/cid/cit804. Epub 2013 Dec 13. No abstract available.

PMID:
24336913
20.

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.

21.

Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI.

PLoS One. 2013 Nov 21;8(11):e80078. doi: 10.1371/journal.pone.0080078. eCollection 2013.

22.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
23.

Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH.

Clin Infect Dis. 2013 Mar;56(6):806-16. doi: 10.1093/cid/cis1007. Epub 2012 Dec 7. Review.

24.

Hepatitis C virus-specific immune responses in noninjecting drug users.

Zeremski M, Makeyeva J, Arasteh K, Des Jarlais DC, Talal AH.

J Viral Hepat. 2012 Aug;19(8):554-9. doi: 10.1111/j.1365-2893.2011.01573.x. Epub 2012 Feb 22.

25.

Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Talal AH, Dimova RB, Seewald R, Peterson RH, Zeremski M, Perlman DC, Des Jarlais DC.

J Subst Abuse Treat. 2013 Jan;44(1):115-9. doi: 10.1016/j.jsat.2012.01.010. Epub 2012 Mar 8.

26.

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.

Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):261-8. doi: 10.1097/QAI.0b013e3182324af9.

27.

CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.

Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH.

J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.

28.

Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.

Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH.

J Hepatol. 2011 Sep;55(3):545-553. doi: 10.1016/j.jhep.2010.12.033. Epub 2011 Jan 21.

29.

Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.

Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH.

J Viral Hepat. 2012 Jan;19(1):47-54. doi: 10.1111/j.1365-2893.2010.01411.x. Epub 2010 Dec 3.

30.

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH.

J Infect Dis. 2009 Dec 1;200(11):1774-80. doi: 10.1086/646614.

PMID:
19848607
31.

More rare birds, and the occasional swan.

Edlin BR, Shu MA, Winkelstein E, Des Jarlais DC, Busch MP, Rehermann B, O'Brien TR, Talal AH, Tobler LH, Zeremski M, Beeder AB.

Gastroenterology. 2009 Jun;136(7):2412-4. doi: 10.1053/j.gastro.2009.04.040. Epub 2009 May 3. No abstract available.

32.

Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH.

Hepatology. 2008 Nov;48(5):1440-50. doi: 10.1002/hep.22500.

33.

Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users.

Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR.

J Viral Hepat. 2009 Jan;16(1):10-20. doi: 10.1111/j.1365-2893.2008.01016.x. Epub 2008 Jul 17.

34.

Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patients.

Zeremski M, Talal AH.

Curr Opin HIV AIDS. 2007 Nov;2(6):489-95. doi: 10.1097/COH.0b013e3282f0dcf9.

PMID:
19372932
35.

The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Zeremski M, Petrovic LM, Talal AH.

J Viral Hepat. 2007 Oct;14(10):675-87. Review.

PMID:
17875002
36.

Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.

Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):262-8.

PMID:
17414926
37.

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.

Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH.

J Hepatol. 2007 Jul;47(1):23-30. Epub 2007 Feb 22.

38.

Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis.

Zeremski M, Talal AH.

Clin Infect Dis. 2006 Aug 1;43(3):373-6. Epub 2006 Jun 22. No abstract available.

PMID:
16804854
39.

Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas.

Kichina JV, Zeremski M, Aris L, Gurova KV, Walker E, Franks R, Nikitin AY, Kiyokawa H, Gudkov AV.

Oncogene. 2006 Feb 9;25(6):857-66.

PMID:
16170338
40.

Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients?

Zeremski M, Talal AH.

J Hepatol. 2005 Jul;43(1):2-5. Review. No abstract available.

PMID:
15922482
41.

Transcription regulation by histone deacetylases.

Wang S, Yan-Neale Y, Zeremski M, Cohen D.

Novartis Found Symp. 2004;259:238-45; discussion 245-8, 285-8. Review.

PMID:
15171258
42.

Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.

Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J, Asselbergs F, Hampton G, Cohen D.

Oncogene. 2003 Sep 18;22(40):6204-13.

PMID:
13679859
43.

Histone deacetylase dHDAC4 is involved in segmentation of the Drosophila embryo and is regulated by gap and pair-rule genes.

Zeremski M, Stricker JR, Fischer D, Zusman SB, Cohen D.

Genesis. 2003 Jan;35(1):31-8.

PMID:
12481296
44.

Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex.

Skowyra D, Zeremski M, Neznanov N, Li M, Choi Y, Uesugi M, Hauser CA, Gu W, Gudkov AV, Qin J.

J Biol Chem. 2001 Mar 23;276(12):8734-9. Epub 2000 Dec 15.

45.

Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function.

Zeremski M, Hill JE, Kwek SS, Grigorian IA, Gurova KV, Garkavtsev IV, Diatchenko L, Koonin EV, Gudkov AV.

J Biol Chem. 1999 Nov 5;274(45):32172-81.

46.

Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus.

Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, Gudkov AV.

Cancer Res. 1997 Dec 1;57(23):5217-20.

47.

Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34.

Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov AV.

Somat Cell Mol Genet. 1997 May;23(3):233-6.

PMID:
9330636
48.

Elk-1 can recruit SRF to form a ternary complex upon the serum response element.

Latinkić BV, Zeremski M, Lau LF.

Nucleic Acids Res. 1996 Apr 1;24(7):1345-51.

49.

Discovering distinct genes represented in 29,570 clones from infant brain cDNA libraries by applying sequencing by hybridization methodology.

Milosavljevic A, Zeremski M, Strezoska Z, Grujic D, Dyanov H, Batus S, Salbego D, Paunesku T, Soares MB, Crkvenjakov R.

Genome Res. 1996 Feb;6(2):132-41.

50.

Clone clustering by hybridization.

Milosavljević A, Strezoska Z, Zeremski M, Grujić D, Paunesku T, Crkvenjakov R.

Genomics. 1995 May 1;27(1):83-9.

PMID:
7665186

Supplemental Content

Loading ...
Support Center